The study was designed to test DNA Aβ42 immunization in mice as alternative approach for possible active immunotherapy in Alzheimer patients. As results, we found polarized Th2 immune responses, efficient Aβ42 antibody levels, and disappearance of antigen specific T cells. In-vivo TNFRSF4/25 antibody co-stimulation enhanced Aβ42 specific T cell responses with initial Th2 expansion and subsequent development of Aβ42 specific CD4 + CD25 + Foxp3+ cells. It showed that Th2 biased responses due to gene gun immunizations propagate the development of regulatory T cells. In conclusion, full-length DNA Aβ42 immunization into skin results in a regulatory response with minimal risk of inflammation and autoimmunity.
Introduction
We are interested in characterizing the immune response in an immunotherapeutic approach for Alzheimer disease using DNA Aβ1-42 immunization. Following the complications due to inflammatory T cell responses in a clinical trial, in which AD patients received active full-length Aβ42 peptide immunizations (AN1792), many therapy approaches are now concentrating on the B cell epitope or using passive immunizations to avoid negative side effects (Mangialasche et al., 2010; Carrillo et al., 2013; Lambracht-Washington and Rosenberg, 2013) . We are pursuing immunization with a DNA encoding three copies of fulllength Aβ1-42 peptide for several reasons: 1) The immune response elicited by DNA immunization differs significantly from Aβ1-42 peptide induced immune responses, 2) the immunization with full-length DNA Aβ1-42 provides the basis for a wider epitope spectrum and 3) we found the disappearance of antigen specific T cells and propose the development of a regulatory T cell response (Lambracht-Washington et al., 2011 , 2012 . It might be beneficial for several reasons when a complete immune response, encompassing B and T cell responses, is addressed within a potential vaccine. B cell epitopes are important for the antibody specificity but antigen specific T cell help improves antibody production and antigen specific regulatory T cells modulate the immune responses.
Antibody treatment with agonistic antibodies binding to receptors of the TNF superfamily, TNF receptor superfamily 4 (TNFRSF4) and TNFRSF25, had been described to expand CD4 + CD25 + Foxp3 + regulatory T cells (Tregs) in mice in-vivo. The published data showed expansion of CD4 + CD25 + Foxp3 + cells in the context of costimulation or vaccination with a peak value at 5 to 6 days which was the half-life of the antibodies (Schreiber et al., 2010 (Schreiber et al., , 2012 Wolf et al., 2012; Khan et al., 2013) . Thus, the possible expansion of antigen specific Tregs cells with this type of co-stimulation with DNA Aβ42 immunization prompted us to further characterize the T cell site. We emphasize that we used this antibody treatment only as a tool to enable the characterization of the T cell response in our model and to demonstrate potential benefits of a Th2/regulatory immune response. Characteristic features of the immune responses following DNA Aβ42 immunization were enhanced due to the co-stimulation which contributed to the overall clarity of the data shown here.
Immunizations and immunotherapy have a broader clinical use, for instance immunizations against a bacterial antigen provide protection from disease caused by the respective organism, or in the context of autoimmunity it has been shown that immunizations which result in the expansion of Tregs can reduce the outcome of an inflammatory event. Immunizations with tumor antigens have been shown successful in treating cancer patients in the prevention of reoccurring cancer cells. In the context of treatment for AD, it is important to state that the
